Literature DB >> 24668476

Nerve growth factor and nociception: from experimental embryology to new analgesic therapy.

Gary R Lewin1, Stefan G Lechner, Ewan St John Smith.   

Abstract

Nerve growth factor (NGF) is central to the development and functional regulation of sensory neurons that signal the first events that lead to pain. These sensory neurons, called nociceptors, require NGF in the early embryo to survive and also for their functional maturation. The long road from the discovery of NGF and its roles during development to the realization that NGF plays a major role in the pathophysiology of inflammatory pain will be reviewed. In particular, we will discuss the various signaling events initiated by NGF that lead to long-lasting thermal and mechanical hyperalgesia in animals and in man. It has been realized relatively recently that humanized function blocking antibodies directed against NGF show remarkably analgesic potency in human clinical trials for painful conditions as varied as osteoarthritis, lower back pain, and interstitial cystitis. Thus, anti-NGF medication has the potential to make a major impact on day-to-day chronic pain treatment in the near future. It is therefore all the more important to understand the precise pathways and mechanisms that are controlled by NGF to both initiate and sustain mechanical and thermal hyperalgesia. Recent work suggests that NGF-dependent regulation of the mechanosensory properties of sensory neurons that signal mechanical pain may open new mechanistic avenues to refine and exploit relevant molecular targets for novel analgesics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24668476     DOI: 10.1007/978-3-642-45106-5_10

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  26 in total

1.  Low-level laser therapy alleviates mechanical and cold allodynia induced by oxaliplatin administration in rats.

Authors:  Y-L Hsieh; Y-C Fan; C-C Yang
Journal:  Support Care Cancer       Date:  2015-05-26       Impact factor: 3.603

Review 2.  Emerging Targets for the Management of Osteoarthritis Pain.

Authors:  Anne-Marie Malfait; Richard J Miller
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

Review 3.  Combining Human and Rodent Genetics to Identify New Analgesics.

Authors:  Alban Latremoliere; Michael Costigan
Journal:  Neurosci Bull       Date:  2017-07-01       Impact factor: 5.203

4.  The NGFR100W Mutation Specifically Impairs Nociception without Affecting Cognitive Performance in a Mouse Model of Hereditary Sensory and Autonomic Neuropathy Type V.

Authors:  Giovanna Testa; Marco Mainardi; Chiara Morelli; Francesco Olimpico; Laura Pancrazi; Carla Petrella; Cinzia Severini; Rita Florio; Francesca Malerba; Antonia Stefanov; Enrica Strettoi; Rossella Brandi; Ivan Arisi; Paul Heppenstall; Mario Costa; Simona Capsoni; Antonino Cattaneo
Journal:  J Neurosci       Date:  2019-11-04       Impact factor: 6.167

5.  Suppression of Peripheral Pain by Blockade of Voltage-Gated Calcium 2.2 Channels in Nociceptors Induces RANKL and Impairs Recovery From Inflammatory Arthritis in a Mouse Model.

Authors:  Uta Baddack; Silke Frahm; Beatriz Antolin-Fontes; Jenny Grobe; Martin Lipp; Gerd Müller; Ines Ibañez-Tallon
Journal:  Arthritis Rheumatol       Date:  2015-06       Impact factor: 10.995

Review 6.  Nerve growth factor: a neuroimmune crosstalk mediator for all seasons.

Authors:  Stephen D Skaper
Journal:  Immunology       Date:  2017-02-21       Impact factor: 7.397

7.  Small-molecule inhibition of STOML3 oligomerization reverses pathological mechanical hypersensitivity.

Authors:  Christiane Wetzel; Simone Pifferi; Cristina Picci; Caglar Gök; Diana Hoffmann; Kiran K Bali; André Lampe; Liudmila Lapatsina; Raluca Fleischer; Ewan St John Smith; Valérie Bégay; Mirko Moroni; Luc Estebanez; Johannes Kühnemund; Jan Walcher; Edgar Specker; Martin Neuenschwander; Jens Peter von Kries; Volker Haucke; Rohini Kuner; James F A Poulet; Jan Schmoranzer; Kate Poole; Gary R Lewin
Journal:  Nat Neurosci       Date:  2016-12-12       Impact factor: 24.884

Review 8.  Nerve growth factor and diarrhea-predominant irritable bowel syndrome (IBS-D): a potential therapeutic target?

Authors:  Xiao-juan Xu; Liang Liu; Shu-kun Yao
Journal:  J Zhejiang Univ Sci B       Date:  2016-01       Impact factor: 3.066

Review 9.  Fibromyalgia syndrome in need of effective treatments.

Authors:  Theoharis C Theoharides; Irene Tsilioni; Lauren Arbetman; Smaro Panagiotidou; Julia M Stewart; Rae M Gleason; Irwin J Russell
Journal:  J Pharmacol Exp Ther       Date:  2015-08-25       Impact factor: 4.030

10.  Functional and Molecular Characterization of Mechanoinsensitive "Silent" Nociceptors.

Authors:  Vincenzo Prato; Francisco J Taberner; James R F Hockley; Gerard Callejo; Alice Arcourt; Bassim Tazir; Leonie Hammer; Paulina Schad; Paul A Heppenstall; Ewan S Smith; Stefan G Lechner
Journal:  Cell Rep       Date:  2017-12-12       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.